Φορτώνει......
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours
BACKGROUND: There is a considerable body of pre-clinical, epidemiological and randomised data to support the hypothesis that aspirin has the potential to be an effective adjuvant cancer therapy. METHODS: Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with...
Αποθηκεύτηκε σε:
Τόπος έκδοσης: | Contemp Clin Trials |
---|---|
Κύριοι συγγραφείς: | , , , , , , , , , , , , |
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
Elsevier
2016
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5127874/ https://ncbi.nlm.nih.gov/pubmed/27777129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cct.2016.10.004 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|